$2.32
0.43%
Nasdaq, Oct 03, 10:00 pm CET
ISIN
US2683111072
Symbol
EDAP

EDAP TMS SA Sponsored ADR Stock price

$2.32
-0.43 15.64% 1M
+0.41 21.47% 6M
+0.11 4.98% YTD
-0.26 10.08% 1Y
-5.78 71.36% 3Y
-2.35 50.32% 5Y
-2.24 49.12% 10Y
-1.23 34.65% 20Y
Nasdaq, Closing price Fri, Oct 03 2025
-0.01 0.43%

Key metrics

Basic
Market capitalization
$87.1m
Enterprise Value
$76.6m
Net debt
positive
Cash
$19.1m
Shares outstanding
37.4m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.2 | 1.2
EV/Sales
1.0 | 1.1
EV/FCF
negative
P/B
2.7
Financial Health
Equity Ratio
47.5%
Return on Equity
-46.5%
ROCE
-62.3%
ROIC
-89.2%
Debt/Equity
0.3
Financials (TTM | estimate)
Revenue
$74.0m | $70.8m
EBITDA
- | $-27.8m
EBIT
$-25.1m | $-30.3m
Net Income
$-24.7m | $-31.1m
Free Cash Flow
$-35.6m
Growth (TTM | estimate)
Revenue
1.1% | -6.0%
EBITDA
- | -31.7%
EBIT
-6.7% | -25.8%
Net Income
-6.9% | -39.1%
Free Cash Flow
-11.5%
Margin (TTM | estimate)
Gross
42.5%
EBITDA
- | -39.3%
EBIT
-33.9%
Net
-33.4% | -43.9%
Free Cash Flow
-48.1%
More
EPS
$-0.7
FCF per Share
$-1.0
Short interest
0.2%
Employees
310
Rev per Employee
$240.0k
Show more

Is EDAP TMS SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,001 stocks worldwide.

EDAP TMS SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a EDAP TMS SA Sponsored ADR forecast:

Buy
67%
Hold
33%

Financial data from EDAP TMS SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
74 74
1% 1%
100%
- Direct Costs 43 43
2% 2%
58%
31 31
5% 5%
42%
- Selling and Administrative Expenses 47 47
8% 8%
63%
- Research and Development Expense 9.68 9.68
-
13%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -25 -25
7% 7%
-34%
Net Profit -25 -25
7% 7%
-33%

In millions USD.

Don't miss a Thing! We will send you all news about EDAP TMS SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

EDAP TMS SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
6 days ago
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option Focal One Robotic HIFU Patient Story Featured on Health Uncensored with Dr. Drew on Lifetime Network  AUSTIN, Texas – September 30, 2025 – EDAP TMS SA (Nasdaq: EDAP), a global leader in robotic energy-based therapies, announced that its non-invasive, nonsurgical treatment option, Focal One Robo...
Neutral
GlobeNewsWire
20 days ago
Focal One® HIFU Receives Prestigious Innovation Award AUSTIN, Texas, September 16, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the company has been honored with the 2025 Industry Award for Innovations in Endourological Instrumentation by the Endourological Society in recognition of its groundbreaking work with the Focal One High-I...
Neutral
GlobeNewsWire
28 days ago
AUSTIN, Texas, September 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Focal One Robotic HIFU procedure for eligi...
More EDAP TMS SA Sponsored ADR News

Company Profile

EDAP TMS SA is a holding company, which through its subsidiary engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses in the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

Head office France
CEO Ryan Rhodes
Employees 310
Founded 1979
Website focalone.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today